The phase 3 MINT study evaluated inebilizumab, a CD-19 directed cytolytic antibody, in 238 patients with gMG, including those who were anti-AChR-Ab+ and anti-MuSK-Ab+.

ACIP votes to change hep B vaccination for infants; positive results for retatrutide; Omisirge approved; counterfeit Ozempic seized by FDA; gene therapy ...

HealthDay News — Federal officials say the US Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and children following COVID-19 vaccination. Federal officials say ...

HealthDay News — Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have been reported. The review covers Beyfortus (from Sanofi ...

Guideline states that prochlorperazine IV and greater occipital nerve blocks must be offered to eligible adults requiring parenteral therapy.

Minimal residual disease is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid leukemia, researchers report.

Congenital HI is a rare genetic condition that results in persistent hypoglycemia due to the overproduction of insulin. Ersodetug, a fully human monoclonal antibody, binds allosterically to insulin ...

Retatrutide treatment resulted in significant improvements in WOMAC pain scores and body weight compared with placebo in the TRIUMPH-4 trial.

Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.

While the CDC report is delayed, non-government researchers are tracking trends in real time. A December 9 report from #WeCount, sponsored by the Society of Family Planning, found that abortions in ...

Pegcetacoplan yields significantly greater change in proteinuria than placebo in C3 glomerulopathy or primary immune-complex MPGN.

GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer.